Q32 Bio Shares Outstanding History (QTTB)
Q32 Bio reported 12.9M shares outstanding at the end of fiscal 2025.
View full Q32 Bio company overviewQ32 Bio annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 12.9M | 660,432 | +5.41% |
| 2024 | 2024-12-31 | 12.2M | 11.8M | +3292.29% |
| 2023 | 2023-12-31 | 359,569 | −57.1M | −99.37% |
| 2022 | 2022-12-31 | 57.5M | 333,636 | +0.58% |
| 2021 | 2021-12-31 | 57.2M | 6.9M | +13.70% |
| 2020 | 2020-12-31 | 50.3M | 5.1M | +11.41% |
| 2019 | 2019-12-31 | 45.1M | 7.8M | +20.77% |
| 2018 | 2018-12-31 | 37.4M | 34.7M | +1316.70% |
| 2017 | 2017-12-31 | 2.6M | — | — |
Q32 Bio quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 23.7M | 11.5M | +94.60% |
| Q1 2026 | 2026-03-31 | 14.6M | 2.4M | +19.94% |
| Q4 2025 | 2025-12-31 | 12.9M | 660,432 | +5.41% |
| Q3 2025 | 2025-09-30 | 12.3M | 165,483 | +1.36% |
| Q2 2025 | 2025-06-30 | 12.2M | 202,409 | +1.69% |
| Q1 2025 | 2025-03-31 | 12.2M | 268,095 | +2.25% |
| Q4 2024 | 2024-12-31 | 12.2M | 11.8M | +3292.29% |
| Q3 2024 | 2024-09-30 | 12.1M | −45.8M | −79.04% |
| Q2 2024 | 2024-06-30 | 12.0M | −45.8M | −79.25% |
| Q1 2024 | 2024-03-31 | 11.9M | −45.9M | −79.36% |
| Q4 2023 | 2023-12-31 | 359,569 | −57.1M | −99.37% |
| Q3 2023 | 2023-09-30 | 57.9M | 421,600 | +0.73% |
| Q2 2023 | 2023-06-30 | 57.8M | 412,555 | +0.72% |
| Q1 2023 | 2023-03-31 | 57.8M | 409,189 | +0.71% |
| Q4 2022 | 2022-12-31 | 57.5M | 333,636 | +0.58% |
| Q3 2022 | 2022-09-30 | 57.5M | 330,632 | +0.58% |
| Q2 2022 | 2022-06-30 | 57.4M | 298,621 | +0.52% |
| Q1 2022 | 2022-03-31 | 57.4M | 6.9M | +13.67% |
| Q4 2021 | 2021-12-31 | 57.2M | 6.9M | +13.70% |
| Q3 2021 | 2021-09-30 | 57.1M | 11.9M | +26.27% |
| Q2 2021 | 2021-06-30 | 57.1M | 11.9M | +26.27% |
| Q1 2021 | 2021-03-31 | 50.5M | 5.3M | +11.68% |
| Q4 2020 | 2020-12-31 | 50.3M | 5.1M | +11.41% |
| Q3 2020 | 2020-09-30 | 45.3M | 1.3M | +2.97% |
| Q2 2020 | 2020-06-30 | 45.2M | 1.3M | +3.06% |
| Q1 2020 | 2020-03-31 | 45.2M | 7.8M | +20.75% |
| Q4 2019 | 2019-12-31 | 45.1M | 7.8M | +20.77% |
| Q3 2019 | 2019-09-30 | 44.0M | 6.6M | +17.81% |
| Q2 2019 | 2019-06-30 | 43.9M | 6.6M | +17.76% |
| Q1 2019 | 2019-03-31 | 37.4M | 34.7M | +1287.93% |
| Q4 2018 | 2018-12-31 | 37.4M | 23.5M | +169.18% |
| Q3 2018 | 2018-09-30 | 37.3M | — | — |
| Q2 2018 | 2018-06-30 | 37.3M | — | — |
| Q1 2018 | 2018-03-31 | 2.7M | — | — |
| Q4 2017 | 2017-12-31 | 13.9M | — | — |
Q32 Bio shares outstanding trends
Over the last five reported fiscal years, Q32 Bio's shares outstanding moved from 50.3M to 12.9M, a change of −37.4M. The latest reported quarter, Q2 2026, shows 23.7M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Q32 Bio filings at SEC.gov ↗